Published in Curr HIV/AIDS Rep on March 01, 2014
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection | NCT01734850
Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. Mol Ther Methods Clin Dev (2016) 0.85
Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene. Mol Ther (2014) 0.85
RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope. Mol Ther Methods Clin Dev (2016) 0.79
Combinatorial hematopoietic stem cell transplantation and vaccination reduces viral pathogenesis following SHIV89.6P-challenge. Gene Ther (2015) 0.76
The social value of candidate HIV cures: actualism versus possibilism. J Med Ethics (2016) 0.75
The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. J Virus Erad (2015) 0.75
RNA interference. Nature (2002) 22.28
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 6.46
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J Virol (1991) 3.94
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature (2011) 3.80
Gene therapy. Intracellular immunization. Nature (1988) 3.60
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol (2002) 3.42
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14
Antibodies in HIV-1 vaccine development and therapy. Science (2013) 3.13
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol (1997) 2.98
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
New paradigms for HIV/AIDS vaccine development. Annu Rev Med (2011) 2.21
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood (2012) 1.85
Challenges in clinical trial design for HIV-1 cure research. Lancet (2013) 1.74
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood (2012) 1.64
Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest (2010) 1.49
Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther (2004) 1.37
Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica (2013) 1.36
Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell (2012) 1.33
Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci U S A (1996) 1.30
Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther (2009) 1.27
Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med (2012) 1.27
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS (2012) 1.26
Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One (2009) 1.19
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther (2005) 1.17
Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A (1998) 1.17
Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother (1998) 1.16
Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood (2008) 1.14
Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood (2013) 1.13
Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol (2012) 1.12
Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood (2012) 1.11
Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med (2005) 1.11
A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther (1998) 1.09
Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther (2013) 0.95
Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Ther (2008) 0.95
Creating genetic resistance to HIV. Curr Opin Immunol (2012) 0.93
Eradication of HIV and Cure of AIDS, Now and How? Front Immunol (2013) 0.92
Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol (2013) 0.91
Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice. Viruses (2013) 0.91
A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther (1999) 0.85
RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J Biol Med (2011) 0.82
A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Hum Gene Ther (1999) 0.81
Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS. Expert Opin Biol Ther (2013) 0.81
Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS (2012) 0.77
Current translational and clinical practices in hematopoietic cell and gene therapy. Cytotherapy (2012) 0.77
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther (2002) 1.85
Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther (2013) 1.49
Lack of association of cytomegalovirus with human brain tumors. Mod Pathol (2005) 1.40
A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 1.21
Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol (2003) 1.20
Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood (2009) 1.14
In vivo evidence insufficient to conclude that "KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission". Blood (2013) 1.08
Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor. Front Immunol (2013) 1.06
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis (2012) 1.03
RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci (2003) 1.03
Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis (2006) 0.98
HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant (2010) 0.98
Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection. Biol Blood Marrow Transplant (2011) 0.96
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. Biol Blood Marrow Transplant (2011) 0.95
Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. Biol Blood Marrow Transplant (2005) 0.94
Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant (2004) 0.94
Creating genetic resistance to HIV. Curr Opin Immunol (2012) 0.93
Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. J Infect Dis (2005) 0.92
Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 0.91
Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice. Viruses (2013) 0.91
DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine (2004) 0.90
Enhanced expression and HIV-1 inhibition of chimeric tRNA(Lys3)-ribozymes under dual U6 snRNA and tRNA promoters. Mol Ther (2002) 0.87
Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. Mol Ther (2002) 0.84
Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation (2002) 0.84
Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J Virol (2003) 0.82
Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma. Leuk Lymphoma (2013) 0.75
KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT). Hum Immunol (2012) 0.75
Death in a gene-therapy trial. N Engl J Med (2009) 0.75